Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study

Levanovich, Peter; Diokno, Ananias C.; Hasenau, Deborah; Lajiness, Michelle J.; Pruchnic, Ryan; Chancellor, Michael B.

doi:10.1007/s11255-015-0924-1

Cited by 36 publications

(29 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study we showed that the ratio of structural markers smoothelin to osteopontin mRNA and not aSMA mRNA, accurately describe the structural changes and loss of in‐vitro contractile properties in the bladder of neurogenic UAB rats. The smoothelin/osteopontin mRNA ratio could serve as a tool to evaluate the effect of new therapies for UAB …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease

Weyne

Dewulf

Deruyer

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

The loss of in-vivo and in-vitro contractile function following pelvic nerve transection is characterized by a switch from a contractile to synthetic SMC phenotype, which is best characterized by the ratio SMTL/OPN mRNA expression. Modulating this phenotypical switch is a potential target for the development of UAB therapy. We suggest for the first time a set of markers that may be useful to evaluate therapeutic strategies on improvements in bladder wall structure.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The smoothelin/osteopontin mRNA ratio could serve as a tool to evaluate the effect of new therapies for UAB. 31…”

Section: Discussionmentioning

confidence: 99%

Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease

Weyne

Dewulf

Deruyer

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…In 2015, Levanovich et al reported a pilot study on intradetrusor injection of adult muscle-derived cells (AMDC) in a human DUA patient [63], a 79-year-old man who had twice undergone transurethral resection of the prostate and suffered from recurrent urinary retention despite the administration of alpha blockers and bethanechol. The patient was on clean intermittent catheterization 4 to 6 times per day but had repeated episodes of gross hematuria and febrile urinary tract infections.…”

Section: Detrusor Underactivity (Dua)mentioning

confidence: 99%

Current and Future Directions of Stem Cell Therapy for Bladder Dysfunction

Shin

Ryu

et al. 2019

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Stem cells are capable of self-renewal and differentiation into a range of cell types and promote the release of chemokines and progenitor cells necessary for tissue regeneration. Mesenchymal stem cells are multipotent progenitor cells with enhanced proliferation and differentiation capabilities and less tumorigenicity than conventional adult stem cells; these cells are also easier to acquire. Bladder dysfunction is often chronic in nature with limited treatment modalities due to its undetermined pathophysiology. Most treatments focus on symptom alleviation rather than pathognomonic changes repair. The potential of stem cell therapy for bladder dysfunction has been reported in preclinical models for stress urinary incontinence, overactive bladder, detrusor underactivity, and interstitial cystitis/bladder pain syndrome. Despite these findings, however, stem cell therapy is not yet available for clinical use. Only one pilot study on detrusor underactivity and a handful of clinical trials on stress urinary incontinence have reported the effects of stem cell treatment. This limitation may be due to stem cell function loss following ex vivo expansion, poor in vivo engraftment or survival after transplantation, or a lack of understanding of the precise mechanisms of action underlying therapeutic outcomes and in vivo behavior of stem cells administered to target organs. Efficacy comparisons with existing treatment modalities are also needed for the successful clinical application of stem cell therapies. This review describes the current status of stem cell research on treating bladder dysfunction and suggests future directions to facilitate clinical applications of this promising treatment modality, particularly for bladder dysfunction.

show abstract

“…Both overactive bladder and underactive detrusor have reported to have improved outcomes in preclinical studies with local injections of adipose derived stem cells ( 14 ). While there have been case reports in human patients the results have been not been completely successful ( 15 ). Bladder augmentation using a tissue engineered bladder has been described in many trials and perhaps is most likely to be adopted clinically ( 16 ).…”

Section: Bladder Augmentation Detrusor Underactivity and Neurogenic mentioning

confidence: 99%

Stem cell in urology—are we at the cusp of a new era?

Panda¹

2018

Transl. Androl. Urol.

View full text Add to dashboard Cite

Stem cell therapy can potentially disrupt conventional medicine as we practice it today. Stem cells can self-renew and differentiate and by this, repair and in certain conditions regenerate damaged tissue. In the past two decades, there has been significant research into its value in several chronic urological conditions for which conventional therapy is unsatisfactory. Stem cell therapy has been tried on animal models of bladder dysfunction, stress urinary incontinence (SUI), erectile dysfunction and urethral injury and certain preclinical studies have had very encouraging results. Yet despite this explosion of knowledge about the nature and value of stem cells, translation of research into the clinical domain has been slow. In addition, lack of regulation of stem cell therapy has resulted in indiscriminate, unscientific administration of stem cell therapy to patients. This review looks into the advances in the use of stem cells in urological practice, the recent regulatory guidelines that have been introduced and what the future holds for this exciting branch.

show abstract

Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study

Cited by 36 publications

References 5 publications

Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease

Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease

Current and Future Directions of Stem Cell Therapy for Bladder Dysfunction

Stem cell in urology—are we at the cusp of a new era?

Contact Info

Product

Resources

About